Pharma trial needs drive Roche's $1.2bn Foundation Medicine deal
This article was originally published in Scrip
Roche is to take a majority stake in molecular information and genomic analysis firm Foundation Medicine (FMI) in a move that could see it invest up to $1.18bn.
You may also be interested in...
The tumor mutational burden biomarker had a much higher profile at this year's ASCO meeting, promising to help target treatment to individuals, though practical barriers remain and testing still is not ready for prime time yet.
Roche used its ASCO investor briefing to highlight its digital and personalized healthcare strategy, including examples of how it’s facilitating R&D and reimbursement – and how that should position it to be an oncology leader in the future.
Roche's potential in the growing field of immuno-oncology has been a game of wait and see. But now that Tecentriq has launched, the company believes the components are in place to maintain its leadership position in oncology.